Waters Parkerson & CO. LLC Has $723,000 Stock Position in GSK plc (NYSE:GSK)

Waters Parkerson & CO. LLC lifted its holdings in shares of GSK plc (NYSE:GSK) by 5.4% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 18,780 shares of the pharmaceutical company’s stock after purchasing an additional 962 shares during the period. Waters Parkerson & CO. LLC’s holdings in GSK were worth $723,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of the business. Dimensional Fund Advisors LP raised its position in GSK by 1.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,777,695 shares of the pharmaceutical company’s stock worth $65,883,000 after purchasing an additional 18,585 shares during the last quarter. Trexquant Investment LP raised its position in shares of GSK by 1,710.6% during the fourth quarter. Trexquant Investment LP now owns 121,746 shares of the pharmaceutical company’s stock worth $4,512,000 after acquiring an additional 115,022 shares during the last quarter. Assetmark Inc. raised its position in shares of GSK by 1,598.7% during the fourth quarter. Assetmark Inc. now owns 2,582 shares of the pharmaceutical company’s stock worth $96,000 after acquiring an additional 2,430 shares during the last quarter. Franklin Resources Inc. lifted its stake in shares of GSK by 0.9% in the fourth quarter. Franklin Resources Inc. now owns 64,336 shares of the pharmaceutical company’s stock worth $2,451,000 after acquiring an additional 602 shares during the period. Finally, Union Savings Bank boosted its holdings in GSK by 15.7% in the fourth quarter. Union Savings Bank now owns 2,928 shares of the pharmaceutical company’s stock valued at $109,000 after acquiring an additional 398 shares during the last quarter. Institutional investors own 15.74% of the company’s stock.

GSK Trading Down 1.8 %

GSK opened at $41.65 on Friday. The company has a market cap of $86.32 billion, a P/E ratio of 15.09, a price-to-earnings-growth ratio of 1.41 and a beta of 0.66. The company has a fifty day moving average price of $41.36 and a two-hundred day moving average price of $41.71. The company has a current ratio of 0.82, a quick ratio of 0.54 and a debt-to-equity ratio of 0.99. GSK plc has a 1-year low of $33.67 and a 1-year high of $45.92.

GSK (NYSE:GSK) last issued its earnings results on Wednesday, July 31st. The pharmaceutical company reported $1.09 EPS for the quarter, beating analysts’ consensus estimates of $1.00 by $0.09. The business had revenue of $9.95 billion during the quarter, compared to analyst estimates of $9.49 billion. GSK had a return on equity of 51.48% and a net margin of 12.87%. Analysts predict that GSK plc will post 4.15 EPS for the current fiscal year.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 10th. Investors of record on Friday, August 16th will be issued a $0.3843 dividend. This is a boost from GSK’s previous quarterly dividend of $0.38. This represents a $1.54 dividend on an annualized basis and a dividend yield of 3.69%. The ex-dividend date of this dividend is Friday, August 16th. GSK’s dividend payout ratio (DPR) is currently 54.71%.

Analysts Set New Price Targets

GSK has been the subject of several analyst reports. Barclays upgraded shares of GSK to a “hold” rating in a report on Tuesday, August 27th. Berenberg Bank upgraded shares of GSK to a “strong-buy” rating in a report on Thursday, June 20th. Jefferies Financial Group upped their price target on shares of GSK from $52.50 to $53.00 and gave the company a “buy” rating in a research report on Tuesday, July 2nd. UBS Group lowered GSK from a “buy” rating to a “neutral” rating in a research report on Monday, July 8th. Finally, The Goldman Sachs Group initiated coverage on GSK in a research report on Thursday, May 30th. They set a “neutral” rating and a $47.00 target price on the stock. Four research analysts have rated the stock with a hold rating, two have given a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $50.00.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.